CD4 and neoplasm: This finding is consistent with the hypothesis that aberrant expression of MHCII expression by TNBC epithelial cells results in the presentation of tumor-specific neoantigens to CD4+ T cells, thus contributing to the host anti-tumor immune response and improving patient outcomes2.